Adult Nodular Sclerosis Hodgkin Lymphoma Completed Phase 2 Trials for Bortezomib (DB00188)

IndicationStatusPhase
DBCOND0030887 (Adult Nodular Sclerosis Hodgkin Lymphoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00082966Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's LymphomaTreatment
NCT00381940Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous TherapyTreatment